RxDoctor Payments Data

Azhar Nisar, MD

Internal Medicine · Dalton, GANPI 1437105046

Payments from drug & device makers

$1,502in general payments, 2019–2025

Across 95 payments — averaging $15.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$358
  • GSK$282
  • Astellas Pharma US Inc$126
  • Kowa Pharmaceuticals America, Inc.$87
  • Sumitomo Pharma America, Inc.$86
  • Amarin Pharma, Inc.$84
  • plus $480 from 13 others

What the payments were for

  • Food & beverage$1,40293%
  • Education$1007%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,502 in reported general payments places this provider in the 70th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$126,689
Medicare patients
169
Services billed
1,436

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide327$390,515
JanuviaSitagliptin Phosphate199$192,131
EliquisApixaban208$152,077
JardianceEmpagliflozin104$107,993
OzempicSemaglutide60$82,026
Trelegy ElliptaFluticasone/Umeclidin/Vilanter96$68,338
VascepaIcosapent Ethyl152$59,294
Breztri AerosphereBudesonide/Glycopyr/Formoterol87$56,652
FarxigaDapagliflozin Propanediol51$54,744
XareltoRivaroxaban47$44,997
XifaxanRifaximin13$41,580
LinzessLinaclotide54$40,488
EntrestoSacubitril/Valsartan43$38,381
Tresiba Flextouch U-200Insulin Degludec39$29,305
TrulicityDulaglutide14$26,760

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$15$417,275341 claims
PfizerEliquis, Premarin$53$158,537220 claims
Boehringer IngelheimJardiance, Trijardy Xr, Combivent Respimat, Synjardy Xr, Spiriva Respimat$36$144,523164 claims
AstraZenecaBreztri Aerosphere, Farxiga, Brilinta, Symbicort$358$131,621191 claims
GSKTrelegy Ellipta, Breo Ellipta$282$88,026130 claims
Novo NordiskOzempic$40$82,02660 claims
AbbVieLinzess$13$40,48854 claims
Astellas Pharma US IncMyrbetriq$126$18,25030 claims
Sumitomo Pharma America, Inc.Gemtesa$86$16,88527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Dalton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →